Table 1 Baseline demographic and clinical characteristics of TANGO II (mCRE-MITT) [14]

From: Clinical Outcomes of Patient Subgroups in the TANGO II Study

Characteristic M-V (n = 32) BAT (n = 15) Total (n = 47)
Age, mean (SD), years 63.5 (14.1) 60.2 (13.0) 62.5 (13.7)
Age cohort, n (%)
 < 65 years 17 (53.1) 9 (60.0) 26 (55.3)
 ≥ 65 years 8 (25.0) 3 (20.0) 11 (23.4)
 ≥ 75 years 7 (21.9) 3 (20.0) 10 (21.3)
Female gender, n (%) 18 (56.3) 5 (33.3) 23 (48.9)
White race, n (%) 28 (87.5) 12 (80.0) 40 (85.1)
BMI, mean (SD) 27.9 (9.0) 25.8 (7.6) 27.2 (8.5)
Infection type, n (%)    
 Bacteremia 14 (43.8) 8 (53.3) 22 (46.8)
 cUTI/AP 12 (37.5) 4 (26.7) 16 (34.0)
 HABP/VABP 4 (12.5) 1 (6.7) 5 (10.6)
 cIAI 2 (6.3) 2 (13.3) 4 (8.5)
Baseline pathogen, n (%)a
 Klebsiella pneumoniae 29 (90.6) 12 (80.0) 41 (87.2)
 Escherichia coli 3 (9.4) 1 (6.7) 4 (8.5)
 Enterobacter cloacae sp. 1 (3.1) 2 (13.3) 3 (6.4)
 Proteus mirabilis 0 (0) 2 (13.3) 2 (4.3)
 Serratia marcescens 1 (3.1) 1 (6.7) 2 (4.3)
Enrolled as confirmed CRE, n (%) 23 (71.9) 14 (93.3) 37 (78.7)
Enrolled as suspected CRE, n (%) 9 (28.1) 1 (6.7) 10 (21.3)
Creatinine clearance, ml/min, n (%)
 ≥ 50 24 (75.0) 9 (60.0) 33 (70.2)
 30–49 4 (12.5) 2 (13.3) 6 (12.8)
 20–29 1 (3.1) 2 (13.3) 3 (6.4)
 < 20 2 (6.3) 0 (0) 2 (4.3)
Missing 1 (3.1) 2 (13.3) 3 (6.4)
Charlson comorbidity index, n (%)
 ≤ 2 4 (12.5) 1 (6.7) 5 (10.6)
 3–4 3 (9.4) 2 (13.4) 5 (10.6)
 5 11 (34.4) 1 (6.7) 12 (25.5)
 ≥ 6 14 (43.8) 11 (73.3) 25 (53.2)
Diabetes mellitus, n (%) 12 (37.5) 7 (46.7) 19 (40.4)
SIRS, n (%) 15 (46.9) 6 (40.0) 21 (44.7)
ICU admission, n (%) 5 (15.6) 3 (20.0) 8 (17.0)
Immunocompromisedb, n (%) 11 (34.4) 8 (53.3) 19 (40.4)
Prior antibiotic failurec, n (%) 9 (28.1) 0 (0) 9 (19.1)
  1. Adapted and reused with permission under open access Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) from Wunderink et al. [14]
  2. BAT best available therapy, BMI body mass index, cIAI complicated intra-abdominal infection, CRE carbapenem-resistant Enterobacteriaceae, cUTI/AP complicated urinary tract infection/acute pyelonephritis, HABP/VABP hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, ICU intensive care unit, mCRE-MITT microbiologic carbapenem-resistant Enterobacteriaceae modified intent-to-treat, M-V meropenem–vaborbactam, SD standard deviation, SIRS systemic inflammatory response syndrome
  3. aBaseline pathogens listed occurred in 2 or more patients
  4. bReceipt of immunosuppressive medications or bone marrow ablative chemotherapy, underlying lymphoma or leukemia (not in remission), previous transplantation, splenectomy, or presence of neutropenia
  5. cClinical evidence of prior antimicrobial failure as ascertained by the study investigator at screening and randomization